--- title: "Competitive Process - Amyloidosis Networked Model of Care" ocid: "ocds-h6vhtk-06b7ee" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06b7ee" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-06b7ee.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-06b7ee.json" source: "Find A Tender Service" current_stage: "Tender" buyer: "NHS ENGLAND" published: "2026-06-18" --- # Competitive Process - Amyloidosis Networked Model of Care Buyer: NHS ENGLAND Current stage: Tender OCID: ocds-h6vhtk-06b7ee [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06b7ee) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-06b7ee.json) ## Summary NHS Arden and Greater East Midlands Commissioning Support Unit, representing NHS England, has initiated a Competitive Process for the commissioning of an Amyloidosis Networked Model of Care in the East of England and South-East regions. This tender, titled "Competitive Process - Amyloidosis Networked Model of Care", falls under the health services category. The procurement method being employed is an open procedure and currently at the tender stage. Interested providers must submit their responses by 12 pm, 21st July 2026. The service delivery is expected to commence in January 2027, with a contract duration of five years, extendable by two years. The total estimated value of the contract is £2,940,000 GBP, evenly split between the two lots covering the respective regions. This procurement offers substantial opportunities for healthcare providers with expertise in rare diseases, specifically amyloidosis. By partaking, providers can expand their footprint within the NHS framework, especially benefitting from collaborating within a networked model to enhance regional expertise, patient access, and service delivery. The successful applicants will have the opportunity to influence the health outcome of patients with a challenging-to-diagnose condition while leveraging the support of Integrated Care Systems. Providers well-suited for this contract will be those with experience in specialised health services and the capability to contribute to sustainable and efficient resource utilisation as part of a network. ## Notice NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of a Amyloidosis Networked Model of Care Service for the East of England and South-East regions. The service is being commissioned under the following Lots: Lot 1 - East of England Lot 2 - South East To participate in the Competitive Process, please register and access documentation via the Atamis (Health Family) portal: https://atamis-1928.my.site.com/s/Welcome Should providers have any queries, or have problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk A provider event via Microsoft Teams is planned for Friday 3rd July 2026 at 11.30am. If you would like to attend, please email anna.salt@nhs.net to register by 5pm on Thursday 2nd July 2026. All slides, questions and responses will be made available to all providers following this event via Atamis. The response deadline is 12pm, midday, on Tuesday 21st July 2026 and the project reference in Atamis is C452273. ### Lot Information Lot 1 - East of England NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of a Amyloidosis Networked Model of Care Service for the East of England and South-East regions. Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein, called amyloid, in organs and tissues throughout the body. The build-up of amyloid proteins (deposits) can make it difficult for the organs and tissues to work properly. Without treatment, this can lead to organ failure and death. This disease presents predominantly in older people and is difficult to diagnose. A highly specialised service (HSS) was commissioned for amyloidosis as it was; * a rare disease * challenging to diagnose outside of a specialist centre and * patients nationally had poor outcomes with high levels of mortality. The service has been commissioned for more than 20 years and there is a single national provider, the National Amyloidosis Centre (NAC); Royal Free London NHS Foundation Trust. The increase in activity has meant that the service has outgrown its capacity and this proposal is to establish a network of providers in England. The network will enable the extension of expertise across the country and improve access for patients. A networked model of care is proposed with four regional centres in the first wave, with an additional two to four to be commissioned later. An initial competitive process was completed in 2025 and resulted in the successful award to two providers for the North West and Midlands regions. This competitive process is being published with the intention of commissioning this service in the East of England and South East regions. This will complete the first wave for this service. The service is being commissioned under the following Lots: Lot 1 - East of England Lot 2 - South East Patients from the rest of the country, where there is not a network centre already, will continue to access care from London until the second wave centres are in place. The devolved nations are not currently part of this network approach. Networks are a vehicle for specialty level collaboration between patients, providers and commissioners. They should have clear lines of accountability with Integrated Care Systems (ICSs) including providers and provider collaboratives, and to NHS England (NHSE) National and Regional Teams, to ensure local ownership, alignment and a local mandate. The network will deliver: * better health, wellbeing and better quality of care for all patients * sustainable and efficient use of NHS resources * supporting the Greener NHS programme by reducing travel * developing regional expertise across specialities * training and succession planning * preserving and enhancing the internationally recognised, high quality, innovative and research based diagnostic and treatment standards for amyloidosis in the UK, with focus on national inclusivity and equity of access * enhanced collaboration, national and regional MDTs * speedier access to specialist treatments * clear pathways and responsibilities for the NAC and the regions The service is due to commence in January 2027 or sooner if possible. The initial contract period is 5 years with Commissioners having the option to extend for up to a further 2 years. The successful Provider(s) in respect of each Lot is expected to be operational, providing services from January 2027. The form of contract to be entered into in respect of each Lot will be in accordance with the general NHS Standard Contract issued by the Commissioner(s), which can be found at: https://www.england.nhs.uk/nhs-standard-contract/ To participate in the Competitive Process, please register and access documentation via the Atamis (Health Family) portal: https://atamis-1928.my.site.com/s/Welcome Should providers have any queries, or have problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk A provider event via Microsoft Teams is planned for Friday 3rd July 2026 at 11.30am. If you would like to attend, please email anna.salt@nhs.net to register by 5pm on Thursday 2nd July 2026. All slides, questions and responses will be made available to all providers following this event via Atamis. The response deadline is 12pm, midday, on Tuesday 21st July 2026 and the project reference in Atamis is C452273. Activity levels and service delivery assumptions are indicative only and may vary over time; providers should design delivery models that are flexible and scalable. Further detail is set out in the Amyloidosis Service Networked Model of Care Service Requirements June 2026 (Document 3). This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The decision maker of the award will be: NHS England - National Commissioning Group. The intention is to award a contracts using the Competitive Process. The announcement by Government, on 13th March 2025, will not disrupt commissioning and contracting of this service. NHS England continues to exist as a statutory body for now. The dissolution of NHS England during the term of the contract will be subject to an act of Parliament and its undertakings will be transferred as appropriate. As and when NHS England is dissolved, commissioning responsibilities will be transferred to an alternative commissioning authority. At this time, the General Condition 12 'Assignment and Sub-Contracting' of the NHS Standard Contract, as per the obligations of the commissioner, will set out the terms and conditions under which the contract will be transferred or assigned to the relevant commissioning authority. Options: There is an option to extend for up to a further 2 years following the initial 5 year contract period. Lot 2 - South East NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of a Amyloidosis Networked Model of Care Service for the East of England and South-East regions. Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein, called amyloid, in organs and tissues throughout the body. The build-up of amyloid proteins (deposits) can make it difficult for the organs and tissues to work properly. Without treatment, this can lead to organ failure and death. This disease presents predominantly in older people and is difficult to diagnose. A highly specialised service (HSS) was commissioned for amyloidosis as it was; * a rare disease * challenging to diagnose outside of a specialist centre and * patients nationally had poor outcomes with high levels of mortality. The service has been commissioned for more than 20 years and there is a single national provider, the National Amyloidosis Centre (NAC); Royal Free London NHS Foundation Trust. The increase in activity has meant that the service has outgrown its capacity and this proposal is to establish a network of providers in England. The network will enable the extension of expertise across the country and improve access for patients. A networked model of care is proposed with four regional centres in the first wave, with an additional two to four to be commissioned later. An initial competitive process was completed in 2025 and resulted in the successful award to two providers for the North West and Midlands regions. This competitive process is being published with the intention of commissioning this service in the East of England and South East regions. This will complete the first wave for this service. The service is being commissioned under the following Lots: Lot 1 - East of England Lot 2 - South East Patients from the rest of the country, where there is not a network centre already, will continue to access care from London until the second wave centres are in place. The devolved nations are not currently part of this network approach. Networks are a vehicle for specialty level collaboration between patients, providers and commissioners. They should have clear lines of accountability with Integrated Care Systems (ICSs) including providers and provider collaboratives, and to NHS England (NHSE) National and Regional Teams, to ensure local ownership, alignment and a local mandate. The network will deliver: * better health, wellbeing and better quality of care for all patients * sustainable and efficient use of NHS resources * supporting the Greener NHS programme by reducing travel * developing regional expertise across specialities * training and succession planning * preserving and enhancing the internationally recognised, high quality, innovative and research based diagnostic and treatment standards for amyloidosis in the UK, with focus on national inclusivity and equity of access * enhanced collaboration, national and regional MDTs * speedier access to specialist treatments * clear pathways and responsibilities for the NAC and the regions The service is due to commence in January 2027 or sooner if possible. The initial contract period is 5 years with Commissioners having the option to extend for up to a further 2 years. The successful Provider(s) in respect of each Lot is expected to be operational, providing services from January 2027. The form of contract to be entered into in respect of each Lot will be in accordance with the general NHS Standard Contract issued by the Commissioner(s), which can be found at: https://www.england.nhs.uk/nhs-standard-contract/ To participate in the Competitive Process, please register and access documentation via the Atamis (Health Family) portal: https://atamis-1928.my.site.com/s/Welcome Should providers have any queries, or have problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk A provider event via Microsoft Teams is planned for Friday 3rd July 2026 at 11.30am. If you would like to attend, please email anna.salt@nhs.net to register by 5pm on Thursday 2nd July 2026. All slides, questions and responses will be made available to all providers following this event via Atamis. The response deadline is 12pm, midday, on Tuesday 21st July 2026 and the project reference in Atamis is C452273. Activity levels and service delivery assumptions are indicative only and may vary over time; providers should design delivery models that are flexible and scalable. Further detail is set out in the Amyloidosis Service Networked Model of Care Service Requirements June 2026 (Document 3). This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The decision maker of the award will be: NHS England - National Commissioning Group. The intention is to award a contracts using the Competitive Process. The announcement by Government, on 13th March 2025, will not disrupt commissioning and contracting of this service. NHS England continues to exist as a statutory body for now. The dissolution of NHS England during the term of the contract will be subject to an act of Parliament and its undertakings will be transferred as appropriate. As and when NHS England is dissolved, commissioning responsibilities will be transferred to an alternative commissioning authority. At this time, the General Condition 12 'Assignment and Sub-Contracting' of the NHS Standard Contract, as per the obligations of the commissioner, will set out the terms and conditions under which the contract will be transferred or assigned to the relevant commissioning authority. Options: There is an option to extend for up to a further 2 years following the initial 5 year contract period. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/057507-2026 | | Notice type | Tender Notice | | Procurement type | Standard | | Procurement category | Services | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Not specified | | All stages | Tender | ## Dates | Field | Value | | --- | --- | | Publication date | 18 Jun 2026 | | Submission deadline | 21 Jul 2026 | | Future notice date | Not specified | | Award date | Not specified | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £2,940,000 | | Lots value | £2,940,000 | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Active | | Lots status | Active | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Locality | LONDON | | Post town | South East London | | Postcode | SE1 8UG | | Country | England | | ITL 1 | TLI London | | ITL 2 | TLI4 Inner London - East | | ITL 3 | TLI45 Lambeth | | Local authority | Lambeth | | Electoral ward | Waterloo & South Bank | | Westminster constituency | Vauxhall and Camberwell Green | | Delivery location | TLH East (England), TLJ South East (England) | ## CPV Codes ### Divisions - 85 - Health and social work services ### Codes - 85100000 - Health services ## Release History - 18 Jun 2026 at 11:02 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/057507-2026 ## Notice URLs - https://atamis-1928.my.site.com/s/Welcome - https://www.ardengemcsu.nhs.uk/ - https://www.england.nhs.uk/ - https://www.england.nhs.uk/nhs-standard-contract/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-06b7ee. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-06b7ee.json.